Adicet Bio completes prula-cel last patient visit
Adicet Bio said the last patient visit for prula-cel is complete and topline SLE data is expected in September 2026. The company also said ADI-212 IND has cleared.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Adicet Bio completes last patient visit for planned prula-cel analysis
Adicet Bio (ACET) said it has completed the last patient visit for the planned analysis of its prula-cel (formerly ADI-001) study in systemic lupus erythematosus with or without lupus nephritis, and provided a corporate update.
Adicet Bio completes last patient visit for prula-cel study
Adicet Bio says last patient visit is complete for planned analysis of prula-cel in systemic lupus erythematosus, with or without lupus nephritis, and provides a corporate update.